The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

References

• De Judicibus MA, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med 2007;14:3-11.
   PubMed Web of Science ®Google Scholar
• Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256:S5-13.
   PubMed Web of Science ®Google Scholar
• Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997;48:74-80.
   PubMed Web of Science ®Google Scholar
• Schumacher GA, Beebe G, Kibler RF, Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;22:552-568.
   Google Scholar
• Yorkston KM, Johnson K, Klasner ER, Getting the work done: a qualitative study of individuals with multiple sclerosis. Disabil Rehabil 2003;25:369-379.
   PubMed Web of Science ®Google Scholar
• McCabe MP, De Judicibus M. The effects of economic disadvantage on psychological well-being and quality of life among people with multiple sclerosis. J Health Psychol 2005;10:163-173.
   PubMedGoogle Scholar
• Stolp-Smith KA, Atkinson EJ, Campion ME, Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology 1998;50:1594-1600.
   PubMed Web of Science ®Google Scholar
• Ford HL, Gerry E, Johnson MH, Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 2001;23:516-521.
   PubMed Web of Science ®Google Scholar
• Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis (Provisional record). Clin Neurol Neurosurg 2002;104:272-275.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, McDowell Z, Wong CK, Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br Med J 1997;314:1580-1583.
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005.
   Google Scholar
• NICE. Guide to the methods of technology appraisal. [online]. 2008. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2008 January 29].
   Google Scholar
• EuroQol Group. EQ-5D: A standardised instrument for use as a measure of health outcome. [online]. Available from URL: http://www.euroqol.org/ [Accessed 2008 8 December].
   Google Scholar
• Furlong W, Feeny D, Torrance G, The Health Utilities Index system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-384.
   PubMed Web of Science ®Google Scholar
• Furlong W, Feeny D, Torrance G, Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI3) system: a technical report: McMaster University, 1998.
   Google Scholar
• The University of Sheffield, Department of Health Economics and Decision Science. About the SF-6D. [online]. 2008. Available from URL: http://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d [Accessed 2008 8 December].
   Google Scholar
• Orme M, Kerrigan J, Tyas D, The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in the United Kingdom (Brief record). Eur J Health Econ 2006;7:S96-104.
   PubMedGoogle Scholar
• Parkin D, Jacoby A, McNamee P, Treatment of multiple sclerosis with interferon (beta): an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68: 144-149.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Lees A, Waugh N, Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. Br Med J 1999;319:1529-1533.
   PubMedGoogle Scholar
• Grima DT, Torrance GW, Francis G, Cost and health related quality of life consequences of multiple sclerosis (Provisional record). Multiple Sclerosis 2000;6:91-98.
   PubMed Web of Science ®Google Scholar
• Jones CA, Pohar SL, Warren S, The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008;6:1.
   PubMed Web of Science ®Google Scholar
• Fisk JD, Brown MG, Sketris IS, A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005;76:58-63.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Smala A, Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC Health Economics in Prevention and Care 2001;2:60-68.
   Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7:534-544.
   Google Scholar
• Berg J, Lindgren P, Fredrikson S, Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7:S75-85.
   PubMedGoogle Scholar
• Henriksson F, Fredrikson S, Masterman T, Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7: 514-523.
   Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7:S24-33.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7:S45-54.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7:S55-64.
   Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7:S65-74.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006;7:S86-95.
   PubMedGoogle Scholar
• Prosser LA, Kuntz KM, Bar-Or A, Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003;9:311-319.
   PubMedGoogle Scholar
• Dolan P, Gudex C, Kind P, A Social Tariff for EuroQol: Results from a UK General Population Survey. York, UK: Center for Health Economics, University of York, 1995.
   Google Scholar
• McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. QJM 1952;21:135-167.
   PubMedGoogle Scholar
• Atlas of MS Database. Global Prevalence of MS [online]. 2009. Available from URL: http://www.atlasofms.org/index.aspx [Accessed 2009 March 11].
   Google Scholar
• Kobelt G, Berg J, Lindgren P, Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis (provisional record). Eur J Health Econ 2006;7:S5-13.
   Google Scholar
• Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87-91.
   PubMed Web of Science ®Google Scholar
• Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008;26:769-779.
   PubMed Web of Science ®Google Scholar
• Dolan P, Sutton M. Mapping visual analogue and standard gamble utilities. Soc Sci Med 1997;44:1519-1530.
   PubMed Web of Science ®Google Scholar
• Gruenewald DA, Higginson IJ, Vivat B, Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler 2004;10:251-255.
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
   Google Scholar